c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target

BMC Cancer

Table 3 Univariate analysis of patients’ 5-year overall survival

Variable	P-value	Hazard ratio (95 % CI)
Age (≥64/<64 years) (mean, 64 years)	0.992	1.003 (0.557–1.809)
Sex (male/female)	0.036^a	2.621 (1.057–8.724)
Tumor size (≥48.7/<48.7 mm) (mean, 48.7 mm)	0.099	1.639 (0.912–2.971)
Tumor differentiation (well/moderate)	0.302	0.682 (0.303–1.390)
(well/poor)	0.143	0.484 (0.185–1.290)
(moderate/poor)	0.41	0.710 (0.340–1.671)
Growth pattern (INFa/INFb)	0.725	0.878 (0.402–1.774)
(INFa/INFc)	0.158	0.528 (0.216–1.290)
(INFb/INFc)	0.193	0.602 (0.297–1.316)
Lymphatic invasion (ly1–3/ly0)	0.015*	2.392 (1.174–5.536)
Venous invasion (v1–3/v0)	0.763	1.109 (0.581–2.295)
Tumor depth (pT3–4/pT1–2)	0.015^a	2.265 (1.164–4.835)
Lymph node metastasis (pN1/pN0)	<0.001^a	4.692 (2.139–12.358)
Distant metastasis (pM1/pM0)	0.086	2.308 (0.875–5.069)
Pathological stage (pStage III–IV/I–II)	<0.001^a	3.403 (1.840–6.620)
c-Met expression (high/low)	0.017^a	2.291 (1.153–5.073)
HGF expression (high/low)	0.194	1.477 (0.817–2.662)

ISSN: 1471-2407